In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

AI's potential for productivity gains may not translate into profits amid fierce competition, BCA's Peter Berezin told BI.

Altimmune, Inc.'s Pemvidutide shows promise in MASH treatment with liver improvements and safety, despite market overreaction. Click for my ALT stock update.

It would behoove more Americans to learn how consistent seafood consumption has strong potential to ward off coronary disease ...

For reference, Novo Nordisk also offers a highly successful weight loss drug, Wegovy, a GLP-1 receptor agonist.

Eli Lilly’s first quarter saw rapid revenue growth, but the market responded negatively due to profit shortfalls and emerging ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

The GLP-1 Exit Plan by Holli Bradish-Lane Holli Bradish-Lane, founder of Iron Crucible Health Coaching, is making waves in ...

GLP-1 obesity drug use is rising, but long-term adherence remains low. While one-year persistence has improved in 2024, only ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year ...

If the drug is more broadly used in people with obesity and not just diabetes, those with higher body weights may see even ...